enGene Therapeutics Inc. Operating Income
enGene Therapeutics Inc. (ENGN) reported Operating Income of -$34.01 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-09-08
- enGene Therapeutics Inc. operating income (loss) for the quarter ending 2026-07-31 was -$34.01M.
- enGene Therapeutics Inc. operating income (loss) for the quarter ending 2026-04-30 was -$31.97M.
- enGene Therapeutics Inc. operating income (loss) for the quarter ending 2026-01-31 was -$31.18M.
- enGene Therapeutics Inc. operating income (loss) for the quarter ending 2025-10-31 was -$39.48M.
- enGene Therapeutics Inc. operating income (loss) for fiscal 2025 was -$123.17M.
- enGene Therapeutics Inc. operating income (loss) for fiscal 2024 was -$62.30M.
- enGene Therapeutics Inc. operating income (loss) for fiscal 2023 was -$26.06M.
- enGene Therapeutics Inc. operating income (loss) for fiscal 2022 was -$19.43M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$34.01M 10-Q · filed 2026-09-08 | -$65.98M derived: sum of 2 quarters · filed 2026-09-08 | -$97.17M 10-Q · filed 2026-09-08 | -$136.65M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | -$31.97M 10-Q · filed 2026-06-15 | -$63.15M 10-Q · filed 2026-06-15 | -$102.63M derived: sum of 3 quarters · filed 2026-06-15 | -$132.58M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | -$31.18M 10-Q · filed 2026-03-09 | -$70.67M derived: sum of 2 quarters · filed 2026-03-09 | -$100.61M derived: sum of 3 quarters · filed 2026-09-08 | -$127.74M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | -$39.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$69.43M derived: sum of 2 quarters · filed 2026-09-08 | -$96.55M derived: sum of 3 quarters · filed 2026-09-08 | -$123.17M 10-K · filed 2025-12-22 |
| 2025-07-31 | -$29.95M 10-Q · filed 2026-09-08 | -$57.07M derived: sum of 2 quarters · filed 2026-09-08 | -$83.68M 10-Q · filed 2026-09-08 | -$101.14M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | -$27.12M 10-Q · filed 2026-06-15 | -$53.74M 10-Q · filed 2026-06-15 | -$71.19M derived: sum of 3 quarters · filed 2026-06-15 | -$87.95M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | -$26.61M 10-Q · filed 2026-03-09 | -$44.07M derived: sum of 2 quarters · filed 2026-03-09 | -$60.83M derived: sum of 3 quarters · filed 2026-03-09 | -$78.14M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | -$17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | -$34.21M derived: sum of 2 quarters · filed 2025-12-22 | -$51.52M derived: sum of 3 quarters · filed 2025-12-22 | -$62.30M 10-K · filed 2025-12-22 |
| 2024-07-31 | -$16.76M 10-Q · filed 2025-09-11 | -$34.07M derived: sum of 2 quarters · filed 2025-09-11 | -$44.84M 10-Q · filed 2025-09-11 | -$55.28M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | -$17.31M 10-Q · filed 2025-06-12 | -$28.08M 10-Q · filed 2025-06-12 | -$38.52M derived: sum of 3 quarters · filed 2025-06-12 | -$44.77M derived: sum of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | -$10.77M 10-Q · filed 2025-03-10 | -$21.21M derived: sum of 2 quarters · filed 2025-03-10 | -$27.46M derived: sum of 3 quarters · filed 2025-03-10 | -$32.20M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | -$10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | -$16.69M derived: sum of 2 quarters · filed 2024-12-19 | -$21.43M derived: sum of 3 quarters · filed 2024-12-19 | -$26.06M 10-K · filed 2024-12-19 |
| 2023-07-31 | -$6.25M 10-Q · filed 2024-09-10 | -$10.98M derived: sum of 2 quarters · filed 2024-09-10 | -$15.62M 10-Q · filed 2024-09-10 | |
| 2023-04-30 | -$4.74M 10-Q · filed 2024-06-14 | -$9.37M 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | -$4.63M 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | -$19.43M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |